330 related articles for article (PubMed ID: 20034863)
1. Prediction of drug-induced cardiotoxicity using human embryonic stem cell-derived cardiomyocytes.
Braam SR; Tertoolen L; van de Stolpe A; Meyer T; Passier R; Mummery CL
Stem Cell Res; 2010 Mar; 4(2):107-16. PubMed ID: 20034863
[TBL] [Abstract][Full Text] [Related]
2. Human embryonic stem cell derived cardiac myocytes detect hERG-mediated repolarization effects, but not Nav1.5 induced depolarization delay.
Qu Y; Gao B; Fang M; Vargas HM
J Pharmacol Toxicol Methods; 2013; 68(1):74-81. PubMed ID: 23518063
[TBL] [Abstract][Full Text] [Related]
3. Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity.
Liang P; Lan F; Lee AS; Gong T; Sanchez-Freire V; Wang Y; Diecke S; Sallam K; Knowles JW; Wang PJ; Nguyen PK; Bers DM; Robbins RC; Wu JC
Circulation; 2013 Apr; 127(16):1677-91. PubMed ID: 23519760
[TBL] [Abstract][Full Text] [Related]
4. Assessment of extracellular field potential and Ca
Abi-Gerges N; Pointon A; Oldman KL; Brown MR; Pilling MA; Sefton CE; Garside H; Pollard CE
J Pharmacol Toxicol Methods; 2017; 83():1-15. PubMed ID: 27622857
[TBL] [Abstract][Full Text] [Related]
5. In vitro electrophysiological drug testing using human embryonic stem cell derived cardiomyocytes.
Caspi O; Itzhaki I; Kehat I; Gepstein A; Arbel G; Huber I; Satin J; Gepstein L
Stem Cells Dev; 2009; 18(1):161-72. PubMed ID: 18510453
[TBL] [Abstract][Full Text] [Related]
6. Automated electrophysiology in the preclinical evaluation of drugs for potential QT prolongation.
Guo L; Guthrie H
J Pharmacol Toxicol Methods; 2005; 52(1):123-35. PubMed ID: 15936217
[TBL] [Abstract][Full Text] [Related]
7. Availability of human induced pluripotent stem cell-derived cardiomyocytes in assessment of drug potential for QT prolongation.
Nozaki Y; Honda Y; Tsujimoto S; Watanabe H; Kunimatsu T; Funabashi H
Toxicol Appl Pharmacol; 2014 Jul; 278(1):72-7. PubMed ID: 24742750
[TBL] [Abstract][Full Text] [Related]
8. CSAHi study: Evaluation of multi-electrode array in combination with human iPS cell-derived cardiomyocytes to predict drug-induced QT prolongation and arrhythmia--effects of 7 reference compounds at 10 facilities.
Kitaguchi T; Moriyama Y; Taniguchi T; Ojima A; Ando H; Uda T; Otabe K; Oguchi M; Shimizu S; Saito H; Morita M; Toratani A; Asayama M; Yamamoto W; Matsumoto E; Saji D; Ohnaka H; Tanaka K; Washio I; Miyamoto N
J Pharmacol Toxicol Methods; 2016; 78():93-102. PubMed ID: 26657830
[TBL] [Abstract][Full Text] [Related]
9. Application of human stem cell-derived cardiomyocytes in safety pharmacology requires caution beyond hERG.
Jonsson MK; Vos MA; Mirams GR; Duker G; Sartipy P; de Boer TP; van Veen TA
J Mol Cell Cardiol; 2012 May; 52(5):998-1008. PubMed ID: 22353256
[TBL] [Abstract][Full Text] [Related]
10. Bridging Functional and Structural Cardiotoxicity Assays Using Human Embryonic Stem Cell-Derived Cardiomyocytes for a More Comprehensive Risk Assessment.
Clements M; Millar V; Williams AS; Kalinka S
Toxicol Sci; 2015 Nov; 148(1):241-60. PubMed ID: 26259608
[TBL] [Abstract][Full Text] [Related]
11. Drug-induced functional cardiotoxicity screening in stem cell-derived human and mouse cardiomyocytes: effects of reference compounds.
Himmel HM
J Pharmacol Toxicol Methods; 2013; 68(1):97-111. PubMed ID: 23702537
[TBL] [Abstract][Full Text] [Related]
12. CSAHi study: Detection of drug-induced ion channel/receptor responses, QT prolongation, and arrhythmia using multi-electrode arrays in combination with human induced pluripotent stem cell-derived cardiomyocytes.
Kitaguchi T; Moriyama Y; Taniguchi T; Maeda S; Ando H; Uda T; Otabe K; Oguchi M; Shimizu S; Saito H; Toratani A; Asayama M; Yamamoto W; Matsumoto E; Saji D; Ohnaka H; Miyamoto N
J Pharmacol Toxicol Methods; 2017; 85():73-81. PubMed ID: 28163191
[TBL] [Abstract][Full Text] [Related]
13. Safety pharmacology assessment of drug-induced QT-prolongation in dogs with reduced repolarization reserve.
Vormberge T; Hoffmann M; Himmel H
J Pharmacol Toxicol Methods; 2006; 54(2):130-40. PubMed ID: 16757186
[TBL] [Abstract][Full Text] [Related]
14. Multi-parametric assessment of cardiomyocyte excitation-contraction coupling using impedance and field potential recording: A tool for cardiac safety assessment.
Zhang X; Guo L; Zeng H; White SL; Furniss M; Balasubramanian B; Lis E; Lagrutta A; Sannajust F; Zhao LL; Xi B; Wang X; Davis M; Abassi YA
J Pharmacol Toxicol Methods; 2016; 81():201-16. PubMed ID: 27282640
[TBL] [Abstract][Full Text] [Related]
15. Electrophysiological evaluation of pentamidine and 17-AAG in human stem cell-derived cardiomyocytes for safety assessment.
Asahi Y; Nomura F; Abe Y; Doi M; Sakakura T; Takasuna K; Yasuda K
Eur J Pharmacol; 2019 Jan; 842():221-230. PubMed ID: 30391349
[TBL] [Abstract][Full Text] [Related]
16. Specific prediction of clinical QT prolongation by kinetic image cytometry in human stem cell derived cardiomyocytes.
Pfeiffer ER; Vega R; McDonough PM; Price JH; Whittaker R
J Pharmacol Toxicol Methods; 2016; 81():263-73. PubMed ID: 27095424
[TBL] [Abstract][Full Text] [Related]
17. Progressive maturation in contracting cardiomyocytes derived from human embryonic stem cells: Qualitative effects on electrophysiological responses to drugs.
Otsuji TG; Minami I; Kurose Y; Yamauchi K; Tada M; Nakatsuji N
Stem Cell Res; 2010 May; 4(3):201-13. PubMed ID: 20199896
[TBL] [Abstract][Full Text] [Related]
18. Early evaluation of compound QT prolongation effects: a predictive 384-well fluorescence polarization binding assay for measuring hERG blockade.
Deacon M; Singleton D; Szalkai N; Pasieczny R; Peacock C; Price D; Boyd J; Boyd H; Steidl-Nichols JV; Williams C
J Pharmacol Toxicol Methods; 2007; 55(3):238-47. PubMed ID: 17141530
[TBL] [Abstract][Full Text] [Related]
19. High-throughput multi-parameter profiling of electrophysiological drug effects in human embryonic stem cell derived cardiomyocytes using multi-electrode arrays.
Clements M; Thomas N
Toxicol Sci; 2014 Aug; 140(2):445-61. PubMed ID: 24812011
[TBL] [Abstract][Full Text] [Related]
20. Proarrhythmia Risk Assessment in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes Using the Maestro MEA Platform.
Qu Y; Vargas HM
Toxicol Sci; 2015 Sep; 147(1):286-95. PubMed ID: 26117837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
